Dapagliflozin Related Severe Weight Loss in a Patient with Lung Cancer

Wang J1,2, Ran F1, Li X3, Jin X4, Bruera E5 and Qian Y1*

1Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2Laboratory of Natural Medicine and Molecular Engineering, College of Plant Science and Technology, Huazhong Agricultural University, Wuhan, China
3Department of Pharmacy, Puren Hospital, Wuhan University of Science and Technology, Wuhan, China
4Department of Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

^*Correspondance to: Yu Qian 

 PDF  Full Text Case Report | Open Access

Abstract:

Cancer cachexia with severe weight loss is recognized as an adverse effect of cancer. Here we present a case of severe weight loss related by dapagliflozin, an antihyperglycemic medication through a mechanism of increasing urinary glucose excretion, in a patient with advanced lung cancer. An unusual feature in our case was that the patient continued to experience severe weight loss while the cancer was quite stable. Increased oral intake was unable to compensate the urinary glucose excretion, but the dose reduction worked, suggesting dapagliflozin as the main reason for weight loss. Our case highlights the usefulness of a full assessment of possible contributors to weight loss, even in patients with cachexia. Identification of reversible causes can have a major effect on the severity of weight loss and overall quality of life for cancer patients.

Keywords:

Cite the Article:

Wang J, Ran F, Li X, Jin X, Bruera E, Qian Y. Dapagliflozin Related Severe Weight Loss in a Patient with Lung Cancer. Ann Clin Case Rep. 2022; 7: 2349..